Mentari Therapeutics Names Todd Shegog to Board, Audit Committee Chair

• Mentari Therapeutics appointed Todd Shegog as director and audit committee chair on November 9, 2026, following its merger with InMed Pharmaceuticals.
• Shegog has more than 30 years of finance, operations, corporate strategy and compliance experience in the biotechnology and pharmaceutical industries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-452706), on November 09, 2026, and is solely responsible for the information contained therein.